Cargando…

Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of Mucopolysaccharidosis Type II

Severe mucopolysaccharidosis type II (MPS II) is a progressive lysosomal storage disease caused by mutations in the IDS gene, leading to a deficiency in the iduronate-2-sulfatase enzyme that is involved in heparan sulphate and dermatan sulphate catabolism. In constitutive form, MPS II is a multi-sys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gleitz, Hélène F. E., O’Leary, Claire, Holley, Rebecca J., Bigger, Brian W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313159/ https://www.ncbi.nlm.nih.gov/pubmed/28207863 http://dx.doi.org/10.1371/journal.pone.0172435

Ejemplares similares

Brain‐targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms
por: Gleitz, Hélène FE, et al.
Publicado: (2018)

Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I
por: Ghosh, Arunabha, et al.
Publicado: (2019)

Haematopoietic stem cell gene therapy with IL‐1Ra rescues cognitive loss in mucopolysaccharidosis IIIA
por: Parker, Helen, et al.
Publicado: (2020)

Neuropathology in Mouse Models of Mucopolysaccharidosis Type I, IIIA and IIIB
por: Wilkinson, Fiona L., et al.
Publicado: (2012)

An investigation of the middle and late behavioural phenotypes of Mucopolysaccharidosis Type-III
por: Cross, Elaine M, et al.
Publicado: (2014)

Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?
por: Horgan, Claire, et al.
Publicado: (2022)

Early defects in mucopolysaccharidosis type IIIC disrupt excitatory synaptic transmission
por: Pará, Camila, et al.
Publicado: (2021)

Intraparenchymal convection enhanced delivery of AAV in sheep to treat Mucopolysaccharidosis IIIC
por: O’Leary, Claire, et al.
Publicado: (2023)

Sustained long-term disease correction in a murine model of MPSII following stem cell gene therapy
por: Ellison, Stuart, et al.
Publicado: (2023)

Heparan Sulfate Inhibits Hematopoietic Stem and Progenitor Cell Migration and Engraftment in Mucopolysaccharidosis I
por: Watson, H. Angharad, et al.
Publicado: (2014)

Association of somatic burden of disease with age and neuropsychological measures in attenuated mucopolysaccharidosis types I, II and VI
por: Ahmed, Alia, et al.
Publicado: (2016)

Airway Abnormalities in Adult Mucopolysaccharidosis and Development of Salford Mucopolysaccharidosis Airway Score
por: Gadepalli, Chaitanya, et al.
Publicado: (2021)

Assessment of Sleep in Children with Mucopolysaccharidosis Type III
por: Mahon, Louise Victoria, et al.
Publicado: (2014)

Orofacial abnormalities in mucopolysaccharidosis and mucolipidosis type II and III: A systematic review
por: de Bode, Chiel J., et al.
Publicado: (2022)

RETRACTED: An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis
por: Wiesinger, Anna-Maria, et al.
Publicado: (2023)

Osteoarthropathy in mucopolysaccharidosis type II
por: NASCU, IOANA, et al.
Publicado: (2013)

Brain RNA-Seq Profiling of the Mucopolysaccharidosis Type II Mouse Model
por: Salvalaio, Marika, et al.
Publicado: (2017)

Actigraphic investigation of circadian rhythm functioning and activity levels in children with mucopolysaccharidosis type III (Sanfilippo syndrome)
por: Mumford, Rachel A., et al.
Publicado: (2015)

Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III
por: Ghosh, Arunabha, et al.
Publicado: (2017)

Cervical spondylolisthesis in mucopolysaccharidosis type II
por: Rossi, Alessandro, et al.
Publicado: (2022)

Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy
por: Pal, Abhijit Ricky, et al.
Publicado: (2018)

Cardiac abnormalities in adults with the attenuated form of mucopolysaccharidosis type I
por: Soliman, O. I. I., et al.
Publicado: (2007)

Skeletal Abnormalities and VDR1 Gene Polymorphisms in Mucopolysaccharidosis Patients
por: Alkhzouz, Camelia, et al.
Publicado: (2021)

Abnormal autophagy, ubiquitination, inflammation and apoptosis are dependent upon lysosomal storage and are useful biomarkers of mucopolysaccharidosis VI
por: Tessitore, Alessandra, et al.
Publicado: (2009)

Non-myeloablative busulfan chimeric mouse models are less pro-inflammatory than head-shielded irradiation for studying immune cell interactions in brain tumours
por: Youshani, A. Saam, et al.
Publicado: (2019)

Proteomic Analysis of Mucopolysaccharidosis IIIB Mouse Brain
por: De Pasquale, Valeria, et al.
Publicado: (2020)

Bone Growth Induction in Mucopolysaccharidosis IVA Mouse
por: Rintz, Estera, et al.
Publicado: (2023)

Review of the use of idursulfase in the treatment of mucopolysaccharidosis II
por: Burrow, T Andrew, et al.
Publicado: (2008)

Biomarkers in patients with mucopolysaccharidosis type II and IV
por: Fujitsuka, Honoka, et al.
Publicado: (2019)

Early enzyme replacement therapy prevents dental and craniofacial abnormalities in a mouse model of mucopolysaccharidosis type VI
por: Nagpal, Rohit, et al.
Publicado: (2022)

Female Mucopolysaccharidosis IIIA Mice Exhibit Hyperactivity and a Reduced Sense of Danger in the Open Field Test
por: Langford-Smith, Alex, et al.
Publicado: (2011)

Clinical Presentation of Mucopolysaccharidosis Type II (Hunter's Syndrome)
por: Chinawa, JM, et al.
Publicado: (2012)

Newborn Screening for Mucopolysaccharidosis Type II in Illinois: An Update
por: Burton, Barbara K., et al.
Publicado: (2020)

Mucopolysaccharidosis Type II: A Kenyan Case Series
por: Mungai, L. N. Wainaina, et al.
Publicado: (2021)

RETRACTED: Wiesinger et al. An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis. Pharmaceutics 2023, 15, 1565
por: Wiesinger, Anna-Maria, et al.
Publicado: (2023)

Visuo‐spatial learning and memory impairments in the 5xFAD mouse model of Alzheimer's disease: Effects of age, sex, albinism, and motor impairments
por: O'Leary, Timothy P., et al.
Publicado: (2022)

Mucopolysaccharidosis VI
por: Valayannopoulos, Vassili, et al.
Publicado: (2010)

An immune deficient mouse model for mucopolysaccharidosis IIIA (Sanfilippo syndrome)
por: Pollock, Kari, et al.
Publicado: (2023)

Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment
por: Giugliani, Roberto, et al.
Publicado: (2010)

Severe tracheal and bronchial collapse in adults with type II mucopolysaccharidosis
por: Rutten, M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8ebamcvg97io416stnjf78476e